在全球GLP-1(胰高糖素样肽-1)药物的竞赛进入白热化阶段之际,全球市值最高的制药企业礼来公司投下了一枚重磅炸弹。 3月11日,礼来宣布,计划未来十年累计投资30亿美元全面扩展在华供应链产能,打造口服固体制剂本土生产与供应体系,着力布局首个申报注册的口服小分子GLP-1受体激动剂orforglipron的生产能力。礼来中国已于2025年底向国家药品监督管理局提交orforglipron用于治疗...
Source Link在全球GLP-1(胰高糖素样肽-1)药物的竞赛进入白热化阶段之际,全球市值最高的制药企业礼来公司投下了一枚重磅炸弹。 3月11日,礼来宣布,计划未来十年累计投资30亿美元全面扩展在华供应链产能,打造口服固体制剂本土生产与供应体系,着力布局首个申报注册的口服小分子GLP-1受体激动剂orforglipron的生产能力。礼来中国已于2025年底向国家药品监督管理局提交orforglipron用于治疗...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.